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osting by EAbstract Aim: Human resistin is an adipokine, which has been suggested to be an inﬂammatory
marker, with possible links to atherosclerosis and coronary heart disease. Meanwhile, the relation-
ship between serum resistin, insulin resistance, and type 2 diabetes mellitus (T2DM) is still contro-
versial. Therefore, this study aimed to assess serum resistin in patients with acute ST-segment
elevation myocardial infarction (STEMI), with and without T2DM.
Patients and methods: A total of 55 subjects included in this study, were categorized into three
groups: 20 non-diabetic patients with acute STEMI (group I), 20 diabetic patients with acute
STEMI (group II), and 15 healthy age and gender-matched controls (group III). Levels of serum
lipids, fasting blood glucose (FBG), insulin, troponin I, creatine kinase (CK), lactate dehydrogenase
(LDH), and resistin, were estimated.
Results: Serum total cholesterol, low density lipoprotein cholesterol (LDLc), FBG, troponin I, CK
(total and MB), LDH, and resistin, were signiﬁcantly higher in group II, than in group I and group
III (p< 0.05). In group II, serum resistin was positively correlated with serum troponin I and TG
(r= 0.59, p< 0.05 and r= 0.47, p< 0.05, respectively), but was negatively correlated with high
density lipoprotein cholesterol (HDLc) (r= 0.46, p> 0.05). However, in this patients’ group,
serum resistin was not correlated with age, gender, body mass index (BMI), total cholesterol,
FBG, insulin, CK, LDH, and the calculated homeostasis model for insulin resistance (HOMA-l.com (H.H. Ibrahim).
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28 H.H. Ibrahim et al.IR) (p> 0.05). As regards group I, serum resistin was not correlated to any of these studied param-
eters (p> 0.05).
Conclusion: Serum resistin levels are elevated in patients with acute STEMI. This increase is more
evident in patients with T2DM than those without T2DM, denoting higher degrees of inﬂamma-
tion. However, serum resistin is not correlated with age, gender, BMI, and insulin resistance. These
data denote that serum resistin concentration might be used as a diagnostic biomarker for acute
STEMI. In addition, optimization of the treatment of T2DM could improve cardioprotection.
ª 2011 Egyptian Society of Cardiology. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
In humans, studies suggest that monocytes and macrophages
produce large quantities of resistin, but rather very little resi-
stin is expressed in adipocytes.1,2
Human resistin (12.5 kDa) is an adipokine which belongs to
a family of small cysteine-rich secretory proteins, named FIZZ
(found in inﬂammatory zone) or resistin-like molecules.3 Res-
istin has been suggested to be an inﬂammatory marker in hu-
mans, because macrophages are known inﬂammatory
modulators. This suggests a possible link between resistin
and cardiovascular (CV) disease via pro-inﬂammatory
pathways.4,5
A number of studies show that the resistin may be involved
in promoting atherosclerosis.6,7 The risk of developing athero-
sclerotic CV disease is known to be 2–4-fold higher in patients
with type 2 diabetes mellitus (T2DM) than in non-diabetic
subjects.8
Chronic sub-clinical inﬂammation has been identiﬁed as an
important mechanism in the pathogenesis of T2DM and asso-
ciated CV complications.9 However, several human studies
have not shown differences in the resistin expression between
normal, insulin-resistant, or patients with T2DM.10–12 Thus,
the role of resistin in human diabetes remains controversial.
Therefore, the aim of our study was to evaluate serum res-
istin in patients with acute myocardial infarction (MI), with
and without T2DM. Moreover, our aim was to correlate ser-
um resistin with clinical and biochemical markers.
2. Patients and methods
This study was carried out among the departments of Cardiol-
ogy, Internal Medicine, and Medical Biochemistry, Faculty of
Medicine, Menoﬁya University, on 55 subjects categorized
into three groups:
Group I: included 20 patients with acute ST segment eleva-
tion myocardial infarction (STEMI) without diabetes melli-
tus (14 males and 6 females) with a mean age of
61.4 ± 7.08 years.
Group II: included 20 patients with acute STEMI with dia-
betes mellitus (13 males and 7 females) with a mean age of
62.1 ± 6.49 years.
Group III: included 15 healthy subjects (10 males and 5
females), matched for age and gender, with a mean age of
58.67 ± 5.58 years, as control group. All controls had no
history of CV disease (including all categories of CHD
and stroke).
Exclusion criteria include all patients who had acute non-
ST segment elevation myocardial infarction (NSTEMI); valvu-lar heart disease; heart failure; hepatic or renal dysfunction;
evidence of active infective, or neoplastic conditions; chronic
inﬂammatory diseases (including rheumatoid arthritis, osteo-
arthritis, inﬂammatory bowel disease); major surgery or trau-
ma,; type 1 DM; or those who were taking
thiazolidinediones (TZD) or insulin. Insulin was considered
to be the main inhibitor of resistin, and TZD effect on resistin
via PPAr-c (peroxisome proliferator activated receptor-c).13
Criteria for the diagnosis of acute STEMI were based on
the European Society of Cardiology/American College of Car-
diology’s redeﬁnition of MI guidelines.14
Participants were classiﬁed as having T2DM if they were
taking oral antidiabetic medication (mainly metformin, glim-
epiride, and/or glibenclamide, in this study), or if they met
2009 American Diabetes Association criteria for the diagnosis
of DM.15
All individuals were subjected to full history taking, clinical
examination, anthropometric measurement of weight and
height with the estimation of body mass index (BMI), and lab-
oratory investigations including: serum lipid proﬁle, troponin
I, total creatine kinase (CK), CK-MB, lactate dehydrogenase
enzyme (LDH), serum resistin, fasting blood glucose (FBG),
fasting insulin level, and calculation of homeostasis model
assessment for insulin resistance (HOMA-IR) according to:
HOMA-IR = fasting glucose (mg/dl) · fasting insulin (lIU/
ml)/405.16
2.1. Sample collection and assay
After taking consent of all studied subjects, 10 ml of fasting ve-
nous blood were withdrawn from all subjects (patients with an
attack of acute MI within 6 h of the appearance of symptoms,
and controls).
One milliliter of venous blood was transferred slowly into a
tube with ﬂuoride, and centrifuged for 10 min. The clear super-
natant was separated in aliquots, kept frozen at 20 C, till the
colorimetric measurement of FBG.17
The rest of venous blood was transferred slowly into a plain
tube, allowed to clot, and then centrifuged for 10 min. The
clear supernatant was separated in several aliquots, kept frozen
at 20 C, till the analysis of the following:
Quantitative determination of total creatine kinase (CK)
and CKMB levels in the serum using commercial kit was sup-
plied by Biosystem Spain.18 Determination of LDH activity
was done by measuring the rate of NADH consumption spec-
trophotometrically which is proportional to the LDH activ-
ity.19 Determination of total cholesterol and triacylglycerides
(TG) was done using colorimetric enzymatic method.20 HDLc
was measured by the precipitation of chylomicrons, VLDL,
and LDL by adding phosphotungstic acid and magnesium ions
to the samples. Centrifugation leaves only the HDL in the
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cally. LDLc was calculated if TG <400 mg/dl by the formula
of Friedewald et al.21
Enzyme linked immunosorbant assay (ELISA) was used for
the quantitative determination of serum troponin I22 and
insulin.23
Resistin assay, using ELISA for the quantitative determina-
tion of resistin hormone was supplied by Ray Biotech. Inc.24
This method of assay employs an antibody speciﬁc for the hu-
man resistin coated on a well plate.
2.2. Statistical analysis
Data were statistically analyzed by SPSS version 11. All data
were presented as a mean ± SD. Statistical differences between
data of the two main patients’ groups, and the control group,
were determined according to F-test. Qualitative data were ex-
pressed as numbers and percentage and analyzed by v2-test.
Correlation between the variables was performed by spearman
correlation coefﬁcient. p values were signiﬁcant if <0.05.
3. Results
There was no signiﬁcant difference in age, gender, and BMI,
among the studied groups (p> 0.05) (Table 1).
Signiﬁcantly higher levels of serum total cholesterol, TG,
LDLc, FBG, insulin, troponin I, total CK (total and MB),
LDH, resistin, as well as calculated HOMA-IR, and signiﬁ-
cantly lower levels of HDLc, in group II than in group I and
group III (p< 0.001).were observed. However, there was no
signiﬁcant difference between serum TG, FBG, insulin, and
calculated HOMA-IR, between group I and group II
(p> 0.05) (Table 2).
There was a signiﬁcantly positive correlation between the
serum resistin level in group II, and each of serum TG, tropo-
nin I, whereas, there was a signiﬁcantly negative correlation
with HDLc (r= 0.59, p< 0.05; r= 0.47, p< 0.05; and
r= 0.46, p> 0.05, respectively). In this group, serum resi-
stin levels had no signiﬁcant correlation with all other param-
eters, i.e. age, gender, BMI, total cholesterol, FBG, insulin,
CK, LDH, and calculated HOMA-IR. On the other hand, as
regards group I, there was no signiﬁcant correlation between
serum resistin and any of these studied parameters (Table 3).
4. Discussion
Resistin appears to be derived from different sources in hu-
mans and animals. Reports point to monocytes and macro-Table 1 Demographic data for all studied groups.
Studied groups Age (year) BMI
Mean ± SD Mean ± SD
Group I (n= 20) 61.4 ± 7.08 22.7 ± 0.84
Group II (n= 20) 62.1 ± 6.49 23.43 ± 5.15
Group III (n= 15) 62.67 ± 3.87 21.93 ± 0.96
Test of signiﬁcance F-test (0.19) F-test (1.38)
p value >0.05 >0.05phages as the main sources of resistin in humans, whereas,
adipocytes are the main source in animals.25,26
In humans, the relationship between resistin and coronary
artery disease (CAD) has been controversial.27 In our study,
we found that the serum resistin levels were signiﬁcantly in-
creased in the patients presented with acute STEMI, when
compared with controls. These results were in agreement with
similar studies done in patients with acute MI.28,29
In line with our results, other reports have similarly re-
ported increased serum resistin levels in patients with CAD.
Reilly et al.30 discovered that the circulating resistin level
was independently associated with coronary artery calciﬁca-
tion (CAC), a quantitative index of atherosclerosis. Also, Bur-
nett et al.,6 reported that the serum resistin levels of premature
coronary artery diseased (PCAD) patients were higher than
normal controls. However, serum resistin levels in our study
were different from the levels found in the last two studies.
These differences could be due to a number of potential
explanations. These two studies examined an earlier stage of
disease, i.e. CAC,30 or angiographically proven PCAD,6
whereas we have measured resistin in the survivors of myocar-
dial infarction, so, it is possible that differences in resistin are
found only early in the course of disease or that those with the
highest resistin levels are dying from their disease and are not
represented in our study. It is also possible that differences in
the resistin levels exist between different ethnic groups. Reilly
et al.,30 reported that median resistin levels in a predominantly
Caucasian population to be 5 ng/ml. Median resistin levels in
patients with PCAD in Caucasians and African-Americans
(using the assay used in this study) were 9 ng/ml, whereas
the median value obtained in this study (2.8 in controls) is
much lower and similar to a previous study in American Indi-
ans.31 These observed differences in serum resistin levels may
reﬂect the impact of genetic or environmental factors on resi-
stin expression.
It is known that inﬂammation and endothelial dysfunction
play a critical role in plaque destabilization and vulnerability.
It has been suggested that resistin may mediate partly its pro-
atherosclerotic properties by inﬂuencing the systemic inﬂam-
mation. Resistin contributes to atherosclerosis partly by mod-
ulating the endothelial function and inciting endothelial
activation.27
Compared with patients who had chronic stable angina, pa-
tients with ACS had coronary plaques with more extensive
macrophage-rich areas, which was the major source of resistin.
Inﬂammatory responses stimulated resistin secretion,32,33 and
resistin could also promote production of pro-inﬂammatory
mediators such as interleukin-6 (IL-6), tumor necrosis factor-Gender
Male Female
No % No %
14 70 6 30
13 65 7 35
10 66.6 5 33.3
v2
>0.05
Table 2 Comparison of biochemical parameters among the studied groups.
Parameters Group I (n= 20) Group II (n= 20) Group III (n= 15) Test of signiﬁcance p value
Mean ± SD Mean ± SD Mean ± SD F-test
Total cholesterol (mg/dl) 203.5 ± 10.69 210.3 ± 9.91 171.53 ± 9.17 70.34 P1 < 0.05*
P2 < 0.001*
P3 < 0.001*
Triglycerides (mg/dl) 110 ± 5.44 166 ± 16.01 92 ± 5.3 242.89 P1 < 0.001*
P2 > 0.05NS
P3 < 0.001*
HDLc (mg/dl) 37.9 ± 1.33 31.8 ± 1.36 48.6 ± 1.5 629.22 P1 < 0.001*
P2 < 0.001*
P3 < 0.001*
LDLc (mg/dl) 143.6 ± 9.89 145.7 ± 10.97 104.6 ± 8.1 90.02 P1 > 0.05NS
P2 < 0.001*
P3 < 0.001*
Fasting blood glucose (mg/dl) 101.15 ± 3.51 194.45 ± 9.71 82.07 ± 5.38 1434.29 P1 < 0.001*
P2 > 0.05NS
P3 < 0.001*
Fasting insulin (lIU/ml) 3.87 ± 0.18 20.97 ± 2.97 4.21 ± 0.58 550.88 P1 < 0.001*
P2 > 0.05NS
P3 < 0.001*
HOMA-IR 0.89 ± 0.04 10.05 ± 1.51 0.82 ± 0.11 641.65 P1 < 0.001*
P2 > 0.05NS
P3 < 0.001*
Troponin I (lg/l) 12.85 ± 1.06 18.08 ± 1.84 0.09 ± 0.01 865.87 P1 < 0.001*
P2 < 0.001*
P3 < 0.001*
CK (Total) (IU/ml) 2000.8 ± 14.63 2226.45 ± 659.31 90.73 ± 5.84 142.06 P1 < 0.05*
P2 < 0.001*
P3 < 0.001*
CK (MB) (IU/ml) 131.05 ± 30.14 136.2 ± 8.21± 21.27±2.25 181.96 P1 < 0.001*
P2 < 0.001*
P3 < 0.001*
LDH (IU/l) 536.1 ± 28.06 551.95 ± 26.38 180.07 ± 10.02 1271.36 P1 < 0.05*
P2 < 0.001 *
P3 < 0.001*
Resistin (ng/ml) 10.07 ± 0.26 17.11 ± 0.67 5.47 ± 0.81 1658.65 P1 < 0.001*
P2 < 0.001*
P3 < 0.001*
HDLc, high density lipoprotein cholesterol; LDLc, low density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment for insulin
resistance; CK, creatine kinase; LDH, lactic acid dehydrogenase; P1, the difference between group I and group II; P2, the difference between
group I and group III; P3, the difference between group II and group III; NS, non-signiﬁcant.
* Signiﬁcant.
30 H.H. Ibrahim et al.a (TNF-a), IL-12, hence aggravate the pro-inﬂammatory re-
sponse. On the other hand resistin could also affect the func-
tions of vascular cells, activate endothelial cells, up-regulate
the expression ET-1, adhesion molecules and chemokines, in-
duce matrix metalloproteinases expression,34 increase CD40 li-
gand signaling by down-regulating the TNF receptor-
associated factor-3. These pro-inﬂammatory mediators have
already been implicated in plaque instability. In addition, res-
istin could also promote lipid accumulation in macrophages.35
Collectively, the above observations suggest that resistin may
have a role in accelerating atherosclerosis, and acts as a desta-
bilizing agent contributing to the occurrence of ACS.
Regarding serum troponin, we found that, serum troponin
I levels were signiﬁcantly higher (like serum resistin) in patients
with STEMI with DM than those without DM. This is com-
patible with the results of Macı´n et al. study.36 Troponins
are known cardio speciﬁc contractile proteins that have high
sensitivity and speciﬁcity for the detection of myocardial dam-age.37,38 The increase of cardiac troponins is associated with
more frequent thrombosis, and impairment of myocardial tis-
sue perfusion.39 Patients with hyperglycemia more often suffer
greater impairment of the cardiac muscle, increased release of
markers of myocardial necrosis, and more severe coronary dis-
eases.40,41 Actually, the presence of DM is associated with sim-
ilar risk to that of previous MI.42 Moreover, elevated serum
glucose concentrations have been independently associated
with negative outcome in those patients.43,44
In human studies, the relationships of circulating resistin to
BMI, insulin sensitivity, and T2DM had been inconsistent.45,46
In our work, we found that plasma concentrations of resistin
were not associated with BMI, insulin resistance, parameters
of glucose, and lipid metabolism, which indicates that the ef-
fect of resistin is independent of BMI and glycemic and lipid
metabolism. This is in accordance with other previous studies.
47,48 In contrast to our work, Mikako et al.,49 found a weak
correlation between serum resistin and BMI. Also, Silha
Table 3 Correlation between serum resistin and various parameters in group I and group II.
Serum resistin (ng/ml)
Group I Group II
Correlation coeﬃcient (r) p value Correlation coeﬃcient (r) p value
Age (years) 0.0 >0.05 0.37 >0.05
Gender 0.12 >0.05 0.09 >0.05
BMI 0.24 >0.05 0.33 >0.05
Total cholesterol (mg/dl) 0.12 >0.05 0.22 >0.05
Triglycerides (mg/dl) 0.19 >0.05 0.59 <0.05*
HDLc (mg/dl) 0.34 >0.05 0.46 <0.05*
LDLc (mg/dl) 0.05 >0.05 0.0 >0.05
Fasting blood glucose (mg/dl) 0.33 >0.05 0.03 >0.05
Fasting insulin (lIU/ml) 0.06 >0.05 0.22 >0.05
HOMA-IR 0.39 >0.05 0.15 >0.05
Troponin I (lg/l) 0.09 >0.05 0.47 <0.05*
CK (total) (IU/ml) 0.1 >0.05 0.02 >0.05
CK (MB) (IU/ml) 0.05 >0.05 0.31 >0.05
LDH (IU/l) 0.34 >0.05 0.17 >0.05
* Signiﬁcant.
Serum resistin in acute myocardial infarction patients with and without diabetes mellitus 31et al.,50 reported that resistin concentrations were not corre-
lated with BMI, although the concentrations were correlated
signiﬁcantly with HOMA-IR.
On the other hand, in vivo human analysis of the relation-
ship between serum resistin and glucose has produced conﬂict-
ing results.51,52 No correlations were identiﬁed in serum
resistin and glucose among non-obese, obese, and obese
T2DM subjects by examining the glucose disposal rate during
a hyperinsulinemic glucose clamp across groups.51 Moreover,
Azuma et al. reported no signiﬁcant correlation in serum resi-
stin and glucose with cross-sectional analysis; but longitudinal
analysis in the same cohort revealed changes in serum resistin
to be positively correlated with glucose as well as other factors
such as BMI, and insulin.52 Hence, these studies may suggest
that cross-sectional analysis of serum resistin may also be inad-
equate to determine correlations. Further, the speciﬁcity of the
resistin ELISA assay emerges as an important factor in these
and other studies; to date, however, only one commercial ELI-
SA appears to have been validated for cross reactivity with dif-
ferent members of the resistin-like molecules (RELM) family
and this may affect the ﬁndings in other studies.48
Acute hyperglycemia is a phenomenon commonly seen in pa-
tients presentedwith acutemyocardial infarction evenwhen they
have never been previously diagnosed with diabetes.44 Close
interrelation between glucose metabolism and inﬂammation
has been shown in several studies. Chronic inﬂammation is in-
volved in an early process in the pathogenesis of diabetes,53
and, conversely, high levels of blood glucose, even in levelswithin
the normal range, promote inﬂammation in the vascular cells.545. Conclusion
Patients with acute STEMI, have signiﬁcantly higher serum
resistin levels (similar to the increased serum troponin I), com-
pared with controls. The levels of resistin (and troponin I) are
much higher in patients with, than those without T2DM,
denoting higher degrees of inﬂammation. Moreover, serum
resistin is correlated with serum troponin I and TG, in patientswith, but not in those without, T2DM. However, it is not cor-
related with age, gender, BMI, and insulin resistance.
Clinical implications of our study include: ﬁrst, serum resi-
stin might play a role as a diagnostic biomarker for acute STE-
MI in patients with or without T2DM. Second, early diagnosis
and treatment of DM are important, since optimization of the
treatment for DM could improve cardioprotection,55 and may
further improve future morbidity and mortality in these
patients.
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